Real time and label free profiling of clinically relevant exosomes

Sina, Abu Ali Ibn, Vaidyanathan, Ramanathan, Dey, Shuvashis, Carrascosa, Laura G., Shiddiky, Muhammad J. A. and Trau, Matt (2016) Real time and label free profiling of clinically relevant exosomes. Scientific Reports, 6 30460: 1-9. doi:10.1038/srep30460

Author Sina, Abu Ali Ibn
Vaidyanathan, Ramanathan
Dey, Shuvashis
Carrascosa, Laura G.
Shiddiky, Muhammad J. A.
Trau, Matt
Title Real time and label free profiling of clinically relevant exosomes
Journal name Scientific Reports   Check publisher's open access policy
ISSN 2045-2322
Publication date 2016-07-28
Year available 2016
Sub-type Article (original research)
DOI 10.1038/srep30460
Open Access Status DOI
Volume 6
Issue 30460
Start page 1
End page 9
Total pages 9
Place of publication London, United Kingdom
Publisher Nature Publishing Group
Collection year 2017
Language eng
Abstract Tumor-derived exosomes possess significant clinical relevance due to their unique composition of genetic and protein material that is representative of the parent tumor. Specific isolation as well as identification of proportions of these clinically relevant exosomes (CREs) from biological samples could help to better understand their clinical significance as cancer biomarkers. Herein, we present a simple approach for quantification of the proportion of CREs within the bulk exosome population isolated from patient serum. This proportion of CREs can potentially inform on the disease stage and enable non-invasive monitoring of inter-individual variations in tumor-receptor expression levels. Our approach utilises a Surface Plasmon Resonance (SPR) platform to quantify the proportion of CREs in a two-step strategy that involves (i) initial isolation of bulk exosome population using tetraspanin biomarkers (i.e., CD9, CD63), and (ii) subsequent detection of CREs within the captured bulk exosomes using tumor-specific markers (e.g., human epidermal growth factor receptor 2 (HER2)). We demonstrate the isolation of bulk exosome population and detection of as low as 10% HER2(+) exosomes from samples containing designated proportions of HER2(+) BT474 and HER2(−) MDA-MB-231 cell derived exosomes. We also demonstrate the successful isolation of exosomes from a small cohort of breast cancer patient samples and identified that approximately 14–35% of their bulk population express HER2.
Q-Index Code C1
Q-Index Status Provisional Code
Institutional Status UQ

Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 0 times in Thomson Reuters Web of Science Article
Scopus Citation Count Cited 0 times in Scopus Article
Google Scholar Search Google Scholar
Created: Fri, 05 Aug 2016, 11:20:34 EST by Mrs Louise Nimwegen on behalf of School of Chemistry & Molecular Biosciences